Cargando…
PB1930: EPIC: A NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FIRST-LINE ACALABRUTINIB THROUGH THE UK EARLY ACCESS PROGRAMME. INTERIM ANALYSIS UP TO 24 MONTHS
Autores principales: | Eyre, Toby, Martinez-Calle, Nicolas, Walewska, Renata, Hickey, Joe, Blak, Betina, Pickin, Anna, Hunjan, Sukhjit, Condon, Orlaith, Hori, Satoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429919/ http://dx.doi.org/10.1097/01.HS9.0000974540.98030.0b |
Ejemplares similares
-
PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022) -
PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023) -
PB1925: NAOS STUDY: FIRST INTERIM ANALYSIS OF ACALABRUTINIB USE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN A REAL-LIFE SETTING.
por: Quinquenel, Anne, et al.
Publicado: (2023) -
PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022) -
PB1876: ACALABRUTINIB RELATED INFECTIOUS COMPLICATIONS-A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHASE III RCT
por: Parmar, K., et al.
Publicado: (2022)